安捷凯在线客服
- 客服:
- 电话: 13061953619
- 微信:
PT2977 (Belzutifan, MK-6482), an orally active and selective HIF-2α inhibitor, increases potency and improves pharmacokinetic profile, providing a potential treatment for clear cell renal cell carcinoma (ccRCC).
PT2977 (Belzutifan, MK-6482), an orally active and selective HIF-2α inhibitor, increases potency and improves pharmacokinetic profile, providing a potential treatment for clear cell renal cell carcinoma (ccRCC).
[1] Xu R, et al. J Med Chem. 2019 Aug 8;62(15):6876-6893.
动态评分
0.0